Preoperatively, a considerable proportion of cases presented with aberrant MCC (51.5%), BC (65.1%), detrusor activity (81.8%), detrusor-sphincter synergy (63.6%), and UDS scores (60.6%). This evidence concerns the gene MCC and breast cancer.